Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12  •  11:03AM ET
4.22
Dollar change
+0.04
Percentage change
0.84
%
IndexRUT P/E- EPS (ttm)-1.45 Insider Own19.84% Shs Outstand112.63M Perf Week28.12%
Market Cap522.15M Forward P/E- EPS next Y-1.11 Insider Trans0.00% Shs Float99.31M Perf Month4.07%
Enterprise Value744.85M PEG- EPS next Q-0.29 Inst Own52.66% Short Float6.07% Perf Quarter31.72%
Income-166.94M P/S6.94 EPS this Y12.76% Inst Trans1.77% Short Ratio5.10 Perf Half Y17.74%
Sales75.21M P/B- EPS next Y21.46% ROA-52.26% Short Interest6.03M Perf YTD111.81%
Book/sh-2.11 P/C2.22 EPS next 5Y21.36% ROE- 52W High4.80 -12.19% Perf Year21.12%
Cash/sh1.89 P/FCF- EPS past 3/5Y18.47% 1.38% ROIC-76.47% 52W Low1.05 301.43% Perf 3Y46.86%
Dividend Est.- EV/EBITDA- Sales past 3/5Y27.82% 97.79% Gross Margin89.33% Volatility11.26% 9.75% Perf 5Y-87.84%
Dividend TTM- EV/Sales9.90 EPS Y/Y TTM39.57% Oper. Margin-162.94% ATR (14)0.36 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.34 Sales Y/Y TTM6.35% Profit Margin-221.97% RSI (14)54.40 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio4.63 EPS Q/Q28.44% SMA205.21% Beta1.94 Target Price8.00
Payout- Debt/Eq- Sales Q/Q-11.03% SMA501.59% Rel Volume0.50 Prev Close4.18
Employees265 LT Debt/Eq- EarningsNov 10 BMO SMA20044.13% Avg Volume1.18M Price4.22
IPOMay 15, 2020 Option/ShortYes / Yes EPS/Sales Surpr.17.42% -2.18% Trades Volume163,793 Change0.84%
Date Action Analyst Rating Change Price Target Change
Nov-08-24Initiated Stephens Overweight $6
May-30-24Initiated Cantor Fitzgerald Overweight
Mar-28-24Initiated Guggenheim Buy $11
Aug-10-23Upgrade JP Morgan Underweight → Neutral
Apr-24-23Downgrade BofA Securities Neutral → Underperform $7 → $2
Dec-06-22Initiated CapitalOne Overweight $12
Nov-09-22Downgrade BofA Securities Buy → Neutral $14 → $7
Sep-21-22Initiated JP Morgan Overweight $5
Sep-09-22Downgrade Morgan Stanley Overweight → Equal-Weight $17 → $11
Nov-09-21Initiated Wolfe Research Outperform $44
Dec-04-25 07:40AM
Dec-03-25 07:30AM
Dec-02-25 04:05PM
Dec-01-25 04:05PM
09:40AM
12:00PM Loading…
Nov-18-25 12:00PM
Nov-10-25 04:01PM
08:40AM
07:30AM
Nov-07-25 12:51PM
07:20AM
Nov-06-25 05:45PM
Nov-03-25 06:05PM
07:15AM
Oct-27-25 07:15AM
06:16AM Loading…
Oct-26-25 06:16AM
Oct-24-25 08:07AM
Oct-13-25 01:06PM
07:30AM
Oct-01-25 04:05PM
Sep-29-25 12:56AM
Sep-18-25 10:34AM
Sep-02-25 04:05PM
Aug-27-25 07:15AM
Aug-13-25 03:07AM
Aug-12-25 03:00PM
07:30AM
Aug-11-25 07:00PM
09:34AM
Aug-07-25 06:10PM
04:05PM Loading…
Aug-05-25 04:05PM
Aug-04-25 09:40AM
Aug-01-25 04:05PM
Jul-01-25 04:05PM
Jun-26-25 11:44AM
Jun-16-25 07:15AM
Jun-12-25 06:45AM
06:30AM
Jun-02-25 04:05PM
May-30-25 05:44AM
May-15-25 07:49AM
07:15AM
May-14-25 09:10AM
08:00AM
07:45AM
May-13-25 09:42AM
May-08-25 05:50PM
07:15AM
May-01-25 05:25PM
Apr-30-25 08:15AM
Apr-29-25 10:01AM
Apr-28-25 10:00AM
07:00AM
Apr-01-25 04:05PM
07:15AM
Mar-31-25 09:00PM
Mar-27-25 11:17AM
08:35AM
07:30AM
Mar-25-25 05:30PM
Mar-24-25 11:08PM
Mar-20-25 07:15AM
Feb-03-25 04:05PM
Jan-30-25 07:15AM
Jan-02-25 04:05PM
Dec-30-24 04:30PM
Dec-11-24 07:30AM
Dec-09-24 07:30AM
Dec-06-24 07:30AM
Dec-02-24 04:30PM
Nov-14-24 02:02AM
Nov-08-24 01:14PM
Nov-07-24 08:50AM
07:30AM
Nov-06-24 07:41AM
Nov-05-24 09:47AM
Nov-04-24 07:15AM
Nov-01-24 04:05PM
09:40AM
Oct-31-24 07:15AM
Oct-01-24 04:05PM
Sep-03-24 04:05PM
07:15AM
Aug-06-24 08:40AM
07:30AM
Aug-01-24 04:05PM
Jul-30-24 07:15AM
Jul-11-24 03:24PM
Jul-08-24 02:00AM
Jul-01-24 04:05PM
Jun-27-24 07:15AM
Jun-13-24 02:31PM
Jun-03-24 04:05PM
May-30-24 07:15AM
May-15-24 07:15AM
May-09-24 07:01PM
07:15AM
May-07-24 08:55AM
08:44AM
May-06-24 10:53AM
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.